Skip to content

A Prospective Randomized Controlled Trial of Intravenous Heparin Combined with Insulin for the Treatment of Hypertriglyceridemic Acute Pancreatitis

A Prospective Randomized Controlled Trial of Intravenous Heparin Combined with Insulin for the Treatment of Hypertriglyceridemic Acute Pancreatitis

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500099001
Enrollment
Unknown
Registered
2025-03-17
Start date
2024-01-08
Completion date
Unknown
Last updated
2025-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperlipidemic induced acute pancreatitis

Interventions

Severe HTG NPO group:NPO
Severe HTG LWMH group:Insulin pump combined with low molecular weight heparin
Very severe HTG LWMH group:Insulin pump combined with low molecular weight heparin
Very severe HTG heparin pump group :Insulin pump combined with heparin pump

Sponsors

The First Affiliated Hospital, School of Medicine, Zhejiang University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Meets diagnostic criteria for acute pancreatitis with a serum triglyceride level >= 11.3mmol/L. 1. Diagnostic criteria for AP: 2 of the following 3 features are required: (1) characteristic abdominal pain; (2) serum amylase and/or lipase = 3 times the upper limit of normal; (3) CT, MRI, or B-ultrasound showing features of pancreatitis; 2. Diagnostic criteria for HTG: serum TG level >= 11.3mmol/L.

Exclusion criteria

Exclusion criteria: 1. Complications requiring surgical treatment 2. Malignancy 3. Pregnant or lactating women 4. Patients with other serious diseases including liver, kidney, and cardiovascular diseases 5. Patients with comorbid psychiatric disorders or severe neuroses 6. Those who are unable to express subjective discomfort symptoms.

Design outcomes

Primary

MeasureTime frame
Organ Failure;Pancreatic necrosis;The risk of developing MSAP/SAP;

Secondary

MeasureTime frame
TG lowering efficacy;Length of hopitalization;Hospital cost;

Countries

China

Contacts

Public ContactMeng Jin

The First Affiliated Hospital, School of Medicine, Zhejiang University

348808620@qq.com+86 188 1301 9371

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026